Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy

Journal of Virology

Volumn 81, Issue 22, 2007, Pages 12145-12155

  Ambrose, Zandrea ^a,f   Palmer, Sarah ^a   Boltz, Valerie F ^a   Kearney, Mary ^a   Larsen, Kay ^b   Polacino, Patricia ^b   Flanary, Leon ^b   Oswald, Kelli ^c   Piatak Jr , Michael ^c   Smedley, Jeremy ^c   Shao, Wei ^a   Bischofberger, Norbert ^d   Maldarelli, Frank ^a   Kimata, Jason T ^e   Mellors, John W ^f   Hu, Shiu Lok ^b   Coffin, John M ^g   Lifson, Jeffrey D ^c   KewalRamani, Vineet N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Washington National Primate Research Center   (United States)

^c SAIC FREDERICK INC   (United States)

^d GILEAD SCIENCES   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACACA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VERTICAL TRANSMISSION; VIREMIA; VIRUS INHIBITION; VIRUS MUTATION; VIRUS TRANSMISSION;

ANIMALS; ANTI-HIV AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MACACA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA NEMESTRINA; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 36048949742     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01301-07     Document Type: Article

References (61)

1. Akiyama, H., E. Ido, W. Akahata, T. Kuwata, T. Miura, and M. Hayami. 2003. Construction and in vivo infection of a new simian/human immunodeficiency virus chimera containing the reverse transcriptase gene and the 3′ half of the genomic region of human immunodeficiency virus type 1. J. Gen. Virol. 84:1663-1669.
2. Ambrose, Z., V. Boltz, S. Palmer, J. M. Coffin, S. H. Hughes, and V. N. Kewalramani. 2004. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J. Virol. 78:13553-13561.
3. Arnedo-Valero, M., F. Garcia, C. Gil, T. Guila, E. Fumero, P. Castro, J. L. Blanco, J. M. Miro, T. Pumarola, and J. M. Gatell. 2005. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin. Infect. Dis. 41:883-890.
4. Ayouba, A., G. Tene, P. Cunin, Y. Foupouapouognigni, E. Menu, A. Kfutwah, J. Thonnon, G. Scarlatti, M. Monny-Lobe, N. Eteki, C. Kouanfack, M. Tardy, R. Leke, M. Nkam, A. E. Nlend, F. Barre-Sinoussi, P. M. Martin, and E. Nerrienet. 2003. Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon. J. Acquir. Immune Defic. Syndr. 34:274-280.
5. + T cells. J. Virol. 80:6441-6457.
6. Balduin, M., S. Sierra, M. P. Daumer, J. K. Rockstroh, M. Oette, G. Fatkenheuer, B. Kupfer, N. Beerenwinkel, D. Hoffmann, J. Selbig, H. J. Pfister, and R. Kaiser. 2005. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J. Clin. Virol. 34:277-287.
7. Barreiro, P., C. de Mendoza, J. Gonzalez-Lahoz, and V. Soriano. 2005. Superiority of protease inhibitors over nonnucleoside reverse- transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption. Clin. Infect. Dis. 41:897-900.
8. Chun, T. W., R. T. Davev, Jr., D. Engel, H. C. Lane, and A. S. Fauci. 1999. Re-emergence of HIV after stopping therapy. Nature 401:874-875.
9. Cline, A. N., J. W. Bess, M. Piatak, Jr., and J. D. Lifson. 2005. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34:303-312.
10. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
11. Cunningham, C. K., M. L. Chaix, C. Rekacewicz, P. Britto, C. Rouzioux, R. D. Gelber, A. Dorenbaum, J. F. Delfraissy, B. Bazin, L. Mofenson, and J. L. Sullivan. 2002. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J. Infect. Dis. 186:181-188.
12. Delwart, E. L., H. Pan, A. Neumann, and M. Markowitz. 1998. Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. J.Virol. 72:2416-2421.
13. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by ihe V3 loop of gp120. J. Virol. 74:8358-8367.
14. Eshleman, S. H., L. A. Guay, A. Mwatha, S. P. Cunningham, E. R. Brown, P. Musoke, F. Mmiro, and J. B. Jackson. 2004. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res. Hum. Retrovir. 20:595-599.
15. Eshleman, S. H., D. R. Hoover, S. E. Hudelson, S. Chen, S. A. Fiscus, E. Piwowar-Manning, J. B. Jackson, N. I. Kumwenda, and T. E. Taha. 2006. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J. Infect. Dis. 193:479-481.
16. Eshleman, S. H., M. Mracna, L. A. Guay, M. Deseyve, S. Cunningham, M. Mirochnick, P. Musoke, T. Fleming, M. Glenn Fowler, L. M. Mofenson, F. Mmiro, and J. B. Jackson. 2001. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15:1951-1957.
17. Faraj, A., L. A. Agrofoglio, J. K. Wakefield, S. McPherson, C. D. Morrow, G. Gosselin, C. Mathe, J. L. Imbach, R. F. Schinazi, and J. P. Sommadossi. 1994. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5′-triphosphate beta enantiomers of cytidine analogs. Antimicrob. Agents Chemother. 38:2300-2305.
18. Flys, T., D. V. Nissley, C. W. Claasen, D. Jones, C. Shi, L. A. Guay, P. Musoke, F. Mmiro, J. N. Strathern, J. B. Jackson, J. R. Eshleman, and S. H. Eshleman. 2005. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis. 192:24-29.
19. Gao, H. Q., P. L. Boyer, S. G. Sarafianos, E. Arnold, and S. H. Hughes. 2000. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J. Mol. Biol. 300:403-418.
20. Garcia, F., M. Plana, C. Vidal, A. Cruceta, W. A. O'Brien, G. Pantaleo, T. Pumarola, T. Gallart, J. M. Miro, and J. M. Gatell. 1999. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 13:F79-F86.
21. Ghosn, J., I. Pellegrin, C. Goujard, C. Deveau, J. P. Viard, J. Galimand, M. Harzic, C. Tamalet, L. Meyer, C. Rouzioux, and M. L. Chaix. 2006. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20:159-170.
22. Goicoechea, M., and B. Best. 2007. Efavirenz/emtricitabine/ tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin. Pharmacother. 8:371-382.
23. Grant, R. M., F. M. Hecht, M. Warmerdam, L. Liu, T. Liegler, C. J. Petropoulos, N. S. Hellmann, M. Chesney, M. P. Busch, and J. O. Kahn. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
24. Guay, L. A., P. Musoke, T. Fleming, D. Bagenda, M. Allen, C. Nakabiito, J. Sherman, P. Bakaki, C. Ducar, M. Deseyve, L. Emel, M. Mirochnick, M. G. Fowler, L. Mofenson, P. Miotti, K. Dransfield, D. Bray, F. Mmiro, and J. B. Jackson. 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala. Uganda: HIVNET 012 randomised trial. Lancet 354:795-802.
25. Han, Y., M. Wind-Rotolo, H. C. Yang, J. D. Siliciano, and R. F. Siliciano. 2007. Experimental approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 5:95-106.
26. Harrigan, P. R., M. Whaley, and J. S. Montaner. 1999. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13:F59-62.
27. Hofman, M. J., J. Higgins, T. B. Matthews, N. C. Pedersen, C. Tan, R. F. Schinazi, and T. W. North. 2004. Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type I. Antimicrob. Agents Chemother. 48:3483-3490.
28. Jackson, J. B., P. Musoke, T. Fleming, L. A. Guay, D. Bagenda, M. Allen, C. Nakabiito, J. Sherman, P. Bakaki, M. Owor, C. Ducar, M. Deseyve, A. Mwatha, L. Emel, C. Duefield, M. Mirochnick, M. G. Fowler, L. Mofenson, P. Miotti, M. Gigliotti, D. Bray, and F. Mmiro. 2003. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362:859-868.
29. Joint United Nations Programme on HIV/AIDS. 2006. Report on the global AIDS epidemic 2006. http:/www.unaids.org/eri/HIV_data/2006GlobalReport/ default.asp.
30. Jourdain, G., N. Ngo-Giang-Huong, S. Le Coeur, C. Bowonwatanuwong, P. Kantipong, P. Leechanachai, S. Ariyadej, P. Leenasirimakul, S. Hammer, and M. Lallemant. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351:229-240.
31. Kimata, J. T., L. Kuller, D. B. Anderson, P. Dailey, and J. Overbaugh. 1999. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5:535-541.
32. Kimata, J. T., A. Mozaffarian, and J. Overbaugh. 1998. A lymph node-derived cytopathic simian immunodeficiency virus Mne variant replicates in nonstimulated peripheral blood mononuclear cells. J. Virol. 72:245-256.
33. Kuritzkes, D. R., H. J. Ribaudo, K. E. Squires, S. L. Koletar, J. Santana, S. A. Riddler, R. Reichman, C. Shikuma, W. A. Meyer III, K. L. Klingman, and R. M. Gulick. 2007. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J. Infect. Dis. 195:1169- 1176.
34. Lallemant, M., G. Jourdain, S. Le Coeur, J. Y. Mary, N. Ngo-Giang-Huong, S. Koetsawang, S. Kanshana, K. McIntosh, and V. Thaineua. 2004. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 351:217-228.
35. Lee, E. J., R. Kantor, L. Zijenah, W. Sheldon, L. Emel, P. Mateta, E. Johnston, J. Wells, A. K. Shetty, H. Coovadia, Y. Maldonado, S. A. Jones, L. M. Mofenson, C. H. Contag, M. Bassett, and D. A. Katzenstein. 2005. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J. Infect. Dis. 192:1260-1264.
36. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomh, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
37. Lockman, S., R. L. Shapiro, L. M. Smeaton, C. Wester, I. Thior, L. Stevens, F. Chand, J. Makhema, C. Moffat, A. Asmelash, P. Ndase, P. Arimi, E. van Widenfelt, L. Mazhani, V. Novitsky, S. Lagakos, and M. Essex. 2007. Response to antiretroviral therapy altera single, peri partum dose of nevirapine. N. Engl. J. Med. 356:135-147
38. Martinson, N. A., L. Morris, G. Gray, D. Moodley, V. Pillay, S. Cohen, P. Dhlamini, A. Puren, S. Bheyroo, J. Steyn, and J. A. McIntyre. 2006. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J. Acquir. Immune Defic. Syndr. 44:148-153.
39. Metzner, K. J., S. Bonhoeffer, M. Fischer, R. Karanicolas, K. Allers, B. Joos, R. Weber, B. Hirschel, L. G. Kostrikis, and H. F. Gunthard. 2003. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J. Infect. Dis. 188:1433-1443.
40. Mirochnick, M., S. Siminski, T. Fenton, M. Lugo, and J. L. Sullivan. 2001. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr. Infect. Dis. J. 20:803-805.
41. Moodley, D., J. Moodley, H. Coovadia, G. Gray, J. McIntyre, J. Hofmyer, C. Nikodem, D. Hall, M. Gigliotti, P. Robinson, L. Boshoff, and J. L. Sullivan. 2003. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J. Infect. Dis. 187:725-735.
42. Muro, E., J. A. Droste, H. T. Hofstede, M. Bosch, W. Dolmans, and D. M. Burger. 2005. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J. Acquir. Immune Defic. Syndr. 39:419-421.
43. Neumann, A. U., R. Tubiana, V. Calvez, C. Robert, T. S. Li, H. Agut, B. Autran, C. Katlama, et al. 1999. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 13:677-683.
44. North, T. W., K. K. Van Rompay, J. Higgins, T. B. Matthews, D. A. Wadford, N. C. Pedersen, and R. F. Sehinazi. 2005. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J. Virol. 79:7349-7354.
45. Office of AIDS Research Advisory Council. 2006. Guidelines for the use of antiretroviral agents in HIV-1-infectcd adults and adolescents. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
46. Palmer, S., V. Boltz, F. Maldarelli, M. Kearney, E. K. Halvas, D. Rock, J. Falloon, R. T. Davey, Jr., R. L. Dewar, J. A. Metcalf, J. W. Mellors, and J. M. Coffin. 2006. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20:701-710.
47. Palmer, S., V. Boltz, N. Martinson, F. Maldarelli, G. Gray, J. McIntyre, J. Mellors, L. Morris, and J. Coffin. 2006. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc. Natl. Acad. Sci. USA 103:7094-7099.
48. Palmer, S., M. Kearney, F. Maldarelli, E. K. Halvas, C. J. Bixby, H. Bazmi, D. Rock, J. Falloon, R. T. Davey, Jr., R. L. Dewar, J. A. Metcalf, S. Hammer, J. W. Mellors, and J. M. Coffin, 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43: 406-413.
49. Pekrun, K., R. Shibata, T. Igarashi, M. Reed, L. Sheppard, P. A. Patten, W. P. Stemmer, M. A. Martin, and N. W. Soong. 2002. Evolution of a human immunodeficiency virus type 1 variant with enhanced replication in pig-tailed macaque cells by DNA shuffling. J. Virol. 76:2924-2935.
50. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
51. Rosenwirth, B., P. ten Haaft, W. M. Bogers, I. G. Nieuwenhuis, H. Niphuis, E. M. Kuhn, N. Bisehofberger, J. L. Heeney, and K. Uberla. 2000. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J. Virol. 74:1704-1711.
52. Shen, A., M. C. Zink, J. L. Mankowski, K. Chadwick, J. B. Margolick, L. M. Carruth, M. Li, J. E. Clements, and R. F. Siliciano. 2003. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J. Virol. 77:4938-4949.
53. Simon, V., and D. D. Ho. 2003. HIV-1 dynamics in vivo: implications for therapy. Nat. Rev. Microbiol. 1:181-190.
54. Simon, V., J. Vanderhoeven, A. Hurley, B. Ramratnam, M. Louie, K. Dawson, N. Parkin, D. Boden, and M. Markowitz. 2002. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16:1511-1519.
55. Soderberg, K., L. Denekamp, S. Nikiforow, K. Sautter, R. C. Desrosiers, and L. Alexander. 2002. A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 76:5803-5806.
56. Srinivas, R. V., and A. Fridland. 1998. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob. Agents Chemother. 42:1484-1487.
57. Taha, T. E., N. I. Kumwenda, D. R. Hoover, S. A. Fiscus, G. Kafulafula, C. Nkhoma, S. Nour, S. Chen, G. Liomha, P. G. Miotti, and R. L. Broadhead. 2004. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 292:202-209.
58. Tobin, N. H., G. H. Learn, S. E. Holte, Y. Wang, A. J. Melvin, J. L. McKernan, D. M. Pawluk, K. M. Mohan, P. F. Lewis, J. I. Mullins, and L. M. Frenkel. 2005. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J. Virol. 79:9625-9634.
59. Uberla, K., C. Stahl-Hennig, D. Bottiger, K. Matz-Rensing, F. J. Kaup, J. Li, W. A. Haseltine, B. Fleckenstein, G. Hunsmann, B. Oberg, et al. 1995. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 92:8210-8214.
60. Wensing, A. M., D. A. van de Vijver, G. Angarano, B. Asjo, C. Balotta, E. Boeri, R. Camacho, M. L. Chaix, D. Costagliola, A. De Luca, I. Derdelinckx, Z. Grossman, O. Hamouda, A. Hatzakis, R. Hemmer, A. Hoepelman, A. Horban, K. Korn, C. Kucherer, T. Leitner, C. Loveday, E. MacRae, I. Maljkovic, C. de Mendoza, L. Meyer, C. Nielsen, E. L. Op de Coul, V. Ormaasen, D. Paraskevis, L. Perrin, E. Puchhammer-Stockl, L. Ruiz, M. Salminen, J. C. Schmit, F. Schneider, R. Schuurman, V. Soriano, G. Stanczak, M. Stanojevic, A. M. Vandamme, K. Van Laethem, M. Violin, K. Wilbe, S. Yerly, M. Zazzi, and C. A. Boucher. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192:958-966.
61. Zuber, B., D. Bottiger, R. Benthin, P. T. Haaft, J. Heeney, B. Wahren, and B. Oberg. 2001. An in vivo model for HIV resistance development. AIDS Res. Hum. Retrovir. 17:631-635.